Toxicities of Immunotherapy for Small Cell Lung Cancer

Yang Fu†, Yue Zheng†, Pei-Pei Wang and Zhen-Yu Ding*

Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China

Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with extremely poor prognosis. In the past two decades, etoposide platinum doublet chemotherapy remained the only choice of therapy, with disappointing overall survival ≤1 year for the metastatic disease. Novel treatments including immunotherapy are urgently needed and extensively explored. Recently, in two phase III trials, atezolizumab and durvalumab were shown to bring survival benefit to patients. While immunotherapy brings better outcome, it is accompanied by adverse events different from traditional treatments. Although these immune-related adverse events (irAEs) are generally mild and can be managed, some irAEs (myocarditis, pneumonitis) may be severe and even life-threatening. Accompanying with the increasing application of immunotherapy in clinical practice, the irAEs should not be overlooked. In this review, the irAEs profile in clinical trials of immunotherapy for SCLC will be summarized, also its unique features compared with irAEs in other malignancies will be explored. This review may be helpful for the appropriate clinical use of immunotherapy for SCLC.

Keywords: small cell lung cancer, immune-related adverse events, neuromuscular toxicity, immune checkpoint inhibitors, death

INTRODUCTION

Small cell lung cancer (SCLC) is a fatal disease, with a 5-year survival less than 7% (1, 2). Platinum doublet chemotherapy, usually combined with etoposide, remains the standard-of-care for decades (3–5). Patients have a high initial response rates of 60%, while most relapse within 6 months and decease within 10 months (5–7).

Immune checkpoint helps to maintain the immune stability, while during carcinogenesis it is hijacked by tumors to evade immune surveillance. Immune checkpoint inhibitors (ICIs) including antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) act to reverse the immunosuppression imparted by tumor cells, either by blocking CTLA-4 pathway or interrupting the interaction between PD-1 and PD-L1 (8, 9). ICI has been widely used in a variety of malignancies, including non-small cell lung cancer, melanoma, triple-negative breast cancer, and non-Hodgkin lymphoma etc. (8, 10–12). Especially in SCLC which has a notorious reputation of poor prognosis, PD-L1 inhibitors including atezolizumab and durvalumab show promising efficacy (9, 13).
While immunotherapy brings better outcome, it is accompanied by adverse events different from traditional treatments. Mounted immune response is directed to not only tumor, but also normal tissues and causes immune-related adverse events (irAEs) (14). Although these irAEs are generally mild and can be managed, some irAEs (myocarditis, pneumonitis) may be severe and even life-threatening (15, 16).

Recently, in two phase III trials (IMPower 133 and CASPIAN), atezolizumab and durvalumab were shown to bring survival benefit to patients (9, 13). Accompanying with the increasing application of immunotherapy in clinical practice, the irAEs should not be overlooked. In SCLC, due to the poor life expectancy, also the high incidence of neurological complications, it is intriguing to ask whether the irAEs would be different from other tumors. This review provided a brief summary of irAEs from published clinical trials in the field of SCLC treatment.

OVERVIEW OF SCLC

SCLC is a distinct form of lung cancer, with dominant component of neuroendocrine tumor cells, and early and frequent distant metastases (17). Mutations in p53 gene (TP53) and retinoblastoma1 gene (RB1) are universal genetic events in SCLC (18). Studies also showed although SCLC harbors a high tumor mutational burden, tumor infiltrating lymphocytes are scarce in the microenvironment (19). Neither SCLC tends to be different from other tumors. This review provided a brief summary of irAEs from published clinical trials in the field of SCLC treatment.

DATA ACQUISITION

All relevant articles are identified by using the keywords “small cell lung cancer,” “SCLC,” “immunotherapy,” “CTLA-4,” “PD-1,” “PD-L1,” “clinical trial” on Pubmed, clinicaltrials.gov, Embase and Web of science. Abstracts and presentation were also reviewed from major conference including ASCO (https://www.asco.org/) and ELCC (https://www.esmo.org/) from 2015 to 2020. The literature or abstract was viewed, and those with only protocol design or lack of AEs results were excluded. Finally, fifteen studies involving ICIs for SCLC therapy with full description of the AEs were selected.

LANDSCAPE OF IMMUNOTHERAPY FOR SCLC

First Line

The first one being tested was ipilimumab, a fully human monoclonal antibody for CTLA-4. Following a successful phase II study (NCT00527735), a phase III trial (CA184-156) investigated the efficacy and safety of ipilimumab combined with chemotherapy (25, 26). However, the addition of ipilimumab failed to demonstrate any improvement in neither OS, ORR, nor duration of response. IMPower133 was a phase III trial to investigate the efficiency of atezolizumab (a humanized monoclonal PD-L1 antibody) combined with chemotherapy. The combination regimen showed benefit in both PFS (5.2 m vs 4.7 m) and OS (12.3 m vs 10.3 m) (9). A similar good outcome was also achieved by durvalumab, another high-affinity human IgG1 monoclonal antibody for PD-L1. In the phase III CASPIAN study, the combination of durvalumab and chemotherapy achieved an OS of 13.3 m (13). The results of PD-1 antibodies seemed less favorably. KEYNOTE-604 was a phase III trial to investigate the efficacy of pembrolizumab (a humanized monoclonal IgG4 antibody) in ES-SCLC patients (27). The results showed that pembrolizumab significantly improves PFS, while OS narrowly had significant difference. Nivolumab is another monoclonal antibody for PD-1. A phase II randomized study (EA5161) evaluated the combination of nivolumab with EP for the ES-SCLC patients. Preliminary results were reported in ASCO 2020, nivolumab significantly improved PFS (5.5 and 4.7 m, p = 0.047) in treated population while OS was no statistical difference (11.3 and 8.5 m, p = 0.14) (28).

Maintenance

A phase III study (CHECKMATE-451) tested either nivolumab monotherapy, or nivolumab plus ipilimumab, or placebo as maintenance therapy after platinum-based first-line chemotherapy. However, nivolumab has a shorter OS compared with placebo (29). Another phase II, single-arm trial (NCT02359019) studied pembrolizumab as maintenance therapy. The 1-year PFS and OS rates were only 13 and 37% respectively (30).

Second Line

Salvage therapy for the relapsed SCLC is more difficult. At least two randomized controlled trial tested the efficacy of immunotherapy. In IFCT-1603 study, atezolizumab monotherapy was compared with topotecan or re-induction of initial chemotherapy (31). A phase III trial CHECKMATE-331 investigated the efficacy and safety of nivolumab monotherapy in the second line of therapy (32). Both trials demonstrated no superiority of immunotherapy over traditional chemotherapy.

Monotherapy seems inappropriate, and following studies tested combination therapy. In a multi-center, single arm, phase II study (NCT02551432), pembrolizumab was combined with chemotherapy drug paclitaxel (33). In another phase II study (NCT02484404), Durvalumab was tested in combination
with olaparib (PARP inhibitors) (34). The preliminary reports of these small sample sized showed promising results.

**Third Line or Later**

Some early, small-scale studies were performed in these very late-staged patients. Nivolumab was the first ICIs approved by FDA for third-line therapy of SCLC, based on the results of CHECKMATE-032 in 2016 (35). KEYNOTE-028 (NCT02054806) and KEYNOTE-158 studies both tested pembrolizumab in the third line therapy. Based on the results, pembrolizumab monotherapy was approved to SCLC in third-line or later (36, 37).

**TOXICITIES**

**Ipilimumab**

In the phase II study (NCT00527735), ipilimumab plus chemotherapy led to higher frequency of AE, either any grade (49 and 43%) or ≥grade 3 (G3, 46 and 30%) AE than chemotherapy alone. Common severe irAEs included G4 diarrhea (n = 1), G3 colitis (n = 1), G4 hepatitis (n = 2), and death (n = 1) attributed to hepatotoxicity (25). In the following phase III study (CA184-156), the combination also had higher incidence of irAEs of all grade (57% in ipilimumab group, and 28% in control) or ≥G3 (20 and 2%). Gastrointestinal and skin toxicity (34 and 29%) were the most common irAEs in ipilimumab group. Endocrine irAEs occurred in 10% of patients in the ipilimumab group including hypothyroidism (3%), hyperthyroidism (2%), hypophysitis (1%), and adrenal insufficiency (1%). Two deaths due to colitis (n = 1) and ulcerative colitis (n = 1) were reported. The incidence of nervous system irAEs was 4% which involved 2% of peripheral sensory neuropathy (26).

**Atezolizumab**

In IMPower133 study, the incidence of AEs was 39.9% in the atezolizumab group and 24.5% in the control group. The most common irAEs was rash (18.7%), hypothyroidism (12.6%), hepatitis (7.1%), and hyperthyroidism (5.6%). The less frequent (≤5%) of irAEs were pneumonitis (2.0%), colitis (1.5%), rhabdomyolysis (1.0%), severe cutaneous reaction (1.0%), pancreatitis (0.5%), nephritis (0.5%), hypophysitis (0.5%), and diabetes mellitus (0.5%). Severe irAEs (≥G3) were rash (2%), hepatitis (1.5%), infusion-related reaction (2%), and colitis (1%) (9). In IFCT-1603 study, the incidence of AE, including 12.5% musculoskeletal or connective tissue disorders, 18.8% gastrointestinal disorders, 4.2% hepatitis, 4.2% colitis, 6.3% arthralgia, 2.1% hyperthyroidism and 2.1% hypothyroidism. No≥G3 irAE was reported (31).

**Durvalumab**

In CASPIAN study, three groups were enrolled, including durvalumab and chemotherapy, combo immunotherapy durvalumab and tremelimumab with chemotherapy, and chemotherapy. The incidences of ≥G3 AEs were 62.3, 70.3, and 62.8% in each of these groups. G5 AEs were 4.9, 10.2 and 5.6%, respectively. For G3–4 irAEs, the incidence was 5% in durvalumab group and ≤1% in control group, and it was 20 and 3% for any grade. Endocrine-related adverse events were the most common irAEs including hypothyroidism (9%), hyperthyroidism (5%), thyroiditis (4%), type 1 diabetes mellitus (T1DM, 2%), rash (2%), and adrenal insufficiency (<1%). The incidence of immune-related pneumonitis was 3% of all grades and 1% of G3–4. There were also reports of immune-related colitis, pancreatic events, and hepatic events. Two immune-related deaths due to hepatotoxicity (n = 1) and pneumonitis (n = 1) were reported (13).

The phase II study (NCT02484404) was an exploratory study. In this study, nine patients (45%) had G3–4 TRAEs including anemia, lymphopenia, thrombocytopenia, and hypophosphatemia. In five patients’ hypothyroidism was observed attributed to immunotherapy (34).

**Pembrolizumab**

In the 1st line setting (KEYNOTE-604), when pembrolizumab used with chemotherapy, the incidence of irAEs (any grade) was 53%, compared with 84% in the control group. Hypothyroidism (10.3%), hyperthyroidism (6.7%), and pneumonitis (4%) were the most common. G3 irAEs occurred in only 7.2% of patients, and no G4–5 irAEs occurred (27). The only maintenance therapy study (NCT02359019) reported three categories of irAEs, rash (n = 8), hypothyroidism (n = 4), T1DM with diabetic ketoacidosis (n = 1) (30). In late lines of pembrolizumab monotherapy (KEYNOTE-028), the most frequent AEs were arthralgia, asthenia, and rash (n = 4 each) as well as diarrhea and fatigue (n = 3 each). Only two patients experienced G3 AE. One had G3 bilirubin elevation, and the other was a lethal case of colitis concurrent with G3 bilirubin elevation. Another similar study (KEYNOTE-158) reported AE of any grade and G3–5 were 33.7 and 5.1%, respectively. Most common irAEs included hypothyroidism (12.1%), hyperthyroidism (6.5%), severe skin reactions (2.8%), adrenal insufficiency, nephritis, pancreatitis, and pneumonitis (1.9% each). G3 AE occurred in six patients, mostly manageable, and no fatal irAE was reported (36, 37). In an early-phase exploratory study (NCT02551432), AEs occurred in all patients. Pneumonia (19.2%), T1DM (7.7%), rash (7.7%), and hypothyroidism (3.9%) were among the most common irAEs. Four patients discontinued treatment (33).

**Nivolumab**

In the study CheckMate-331, TRAEs of all grade (≥G3) occurred in 55% (14%) of nivolumab group, and 90% (73%) of chemotherapy group. There were five treatment-related death, two with nivolumab and three with chemotherapy. The incidences of irAEs (all grade) of endocrine, skin, gastrointestinal, liver, lung and kidney were 12, 11, 7, 5, 1 and <1% respectively (32). In study CheckMate-032, skin toxicity (any grade, 21.1%) was the most common. Other irAEs including endocrine, gastrointestinal, hepatic, pulmonary and renal toxicity were 9.2, 6.4, 4.6, 1.8 and 0.9% respectively. The incidence of G3–4 pneumonitis, rash, aspartate aminotransferase increase was 1.8, 0.9, and 0.9%, respectively.
One immune-related encephalitis (grades 3–4) was reported. One death due to checkpoint inhibitor pneumonitis was noted (35). While in study CheckMate-451, the most frequently occurred serious AEs was pneumonitis (3.8%). Other serious included colitis (3.6%), endocrine (2.5%), hepatitis (0.7%), and nervous system (3.7%). Myocarditis was reported in two cases (0.7%) in group. AEs in nervous system were encephalitis (n = 2), myasthenia gravis (n = 1), and Guillian–Barre syndrome (n = 1). There were eight treatment-related deaths in the nivolumab group versus one in the control group (29). In study EA5161, the incidence of grade 3/4 TRAEs was 77% vs 62%. Treatment-related fatal adverse events were similar in the two groups (n = 9 and 7) (28).

**DISCUSSION**

This review summarized 15 trials in SCLC immunotherapy, including phase III (n = 5) and phase I/II trials (n = 10, Figure 1). Among them, IMpower133, CASPIAN, CA184-156, KEYNOTE-604 and EA5161 evaluated the efficacy of atezolizumab, durvalumab, ipilimumab, pembrolizumab, or nivolumab, when combined with chemotherapy. CheckMate-331 and IFCT-1603 tested the efficacy of nivolumab and atezolizumab monotherapy in 2nd-line. Six trials investigated efficacy and safety of ICIs in later-line or maintenance treatment. Most trials were performed in ICIs combined with chemotherapy. More studies are ongoing (Table 1).

When all the 15 trials combined for analysis, PD-1/PD-L1 inhibitors had a better tolerance than CTLA-4 inhibitors (Figure 2A). Dermal events (23.8%), colitis (5.6%), hepatitis (4.3%), hypophysitis (0.4%), myasthenic (0.3%), and myocarditis (0.3%) were more common with CTLA-4 inhibitors, whereas pneumonitis (3.7%), thyroid events (14.3%), pancreatic events (1.0%), and rheumatic events (0.2%) were more common with PD-1/PD-L1 inhibitors. It was also interesting to observe the difference of toxicities between PD-1 and PD-L1 inhibitors. Generally, the rate of irAE by PD-L1 inhibitors was lower than that of PD-1 inhibitors, including pneumonitis (4.3% vs 2.1%), dermal events (12.4% vs 8.1%), colitis (2.3% vs 1.7%), adrenal insufficiency (0.7% vs 0.2%), nephritis (0.6% vs 0.2%), myositis (0.4% vs 0), rheumatic disease (0.4% vs 0), hyophysitis (0.2% vs 0), and myocarditis (0.1% vs 0, Figure 2B).

In CheckMate-451 trial, the frequency of irAEs of the nivolumab plus ipilimumab group was higher than that of nivolumab group. Not only occurrence, but the severity (frequency of ≥G3 irAEs) was also worse in the combo therapy. Similarly, immunotherapy plus chemotherapy showed better efficacy in IMpower133 and CASPIAN study, but at the price of more irAE events. Furthermore, adding ipilimumab to this combination brought no additional benefit, but significantly higher toxicities.

The exact pathophysiology of irAEs is unclear, but the toxicity between CTLA-4 and PD-L1/PD-1 inhibitors is quite different. Pituitary cells translocate to express CTLA-4. The CTLA-4 antibody binds to the pituitary and induces lymphocyte infiltration, and tissue destruction is triggered (38, 39). PD-L1 was highly expressed on the surface of myocardial cells in two patients with immune myocarditis, leading to the recognition of myocardial and tumor surface antigens by the same T cell clone, which ultimately cause destruction of organ (16). In Keynote001 trial, 10 patients were newly diagnosed with hypothyroidism after receiving pembrolizumab, and eight of them were diagnosed with anti–thyroid antibody (40). It was suggested that irAE may be associated with autoantibodies. CTLA-4 Inhibitors reduce the number and activity of Treg cells, resulting in increased activity of TH17 cells and increased IL-17 release, contributing to the onset of immune-related colitis (41–43).

Because SCLC is a kind of neuroendocrine tumor, also autoimmune encephalitis was frequently reported for this disease, we proposed there might be an increased occurrence of neuromuscular toxicity during the immunotherapy. To test this hypothesis, we performed a pooled analysis of the reported neuromuscular toxicity from the above trials. We found less occurrence in the control group, compared with that in immunotherapy group (Figure 3A). To confirm this observation, we performed a similar analysis in NSCLC trials. Conversely, immunotherapy and control groups had comparable toxicity (Figure 3B). This further supported the notion the neuromuscular toxicity of immunotherapy was specifically restricted in SCLC.

We paid special attention to the fatal toxicities. Immunotherapy and chemotherapy had a similar incidence of treatment-related death for SCLC patients. Totally 36 and 27 death events occurred from seven head-to-head trials respectively (Figure 4). From all the trials, the most common reason of reported death were sepsis (n = 7) and pneumonitis (n = 7), followed by multiorgan failure (n = 3), hematologic...
| Trial          | Treatment | Phase | Intervention | Population | Patients | Therapy                                                                 | Status          |
|---------------|-----------|-------|--------------|------------|----------|--------------------------------------------------------------------------|-----------------|
| NCT02580994  | REACTION  | First line | II | RCT | ES-SCLC  | 125 | Pembrolizumab + EP/EP vs EP/EP | Recruiting      |
| NCT02402920  | First line | Parallel | SCLC  | 80 | Pembrolizumab + Concurrent Chemo/Radiotherapy | Recruiting |
| NCT02963090  | Second line | II | RCT | Relapsed | 98 | Pembrolizumab vs Topotecan | Active          |
| NCT03371979  | Second line | II | Single arm | Relapsed | 84 | Pembrolizumab + Pegylarginase(AEB1102) | Active          |
| NCT04358237  | LUPER     | Second line | II | Single arm | Relapsed | 42 | Pembrolizumab + Lynbrinecein (PM01183) | Not yet recruiting |
| NCT03253068  | Second line | II | Single arm | Relapsed | 25 | Pembrolizumab + Amurubicin | Recruiting |
| NCT04173325  | Second line | I | Single arm | Relapsed | 10 | Nivolumab + Irototecan | Recruiting |
| NCT03496735  | Second line | II | Multicohort | SCLC  | 40 | Nivolumab + Ipiplumumab + Dendritic Cell p53 Vac | Recruiting |
| NCT03865891  | Second line | II | Multicohort | Relapsed | 106 | Nivolumab + Ipiplumumab | Recruiting |
| NCT03670056  | Second line | II | Single arm | Relapsed | 55 | Nivolumab + Ipiplumumab + Piranbulin | Recruiting |
| NCT03728361  | Second line | II | Single arm | Relapsed | 14 | Nivolumab + Gomcatbine | Active          |
| NCT0357593   | Second line | I/II | Parallel | Relapsed | 172 | BMS-986012 + Nivolumab vs BMS-986012 | Active          |
| NCT0325816   | Maintenance | I/II | Single arm | ES-SCLC  | 9 | Nivolumab + Luithera | Active          |
| NCT03958045  | Maintenance | II | Single arm | SCLC  | 36 | Nivolumab + Rucaparib | Recruiting |
| NCT02046733  | STIMULI   | Maintenance | II | Parallel | LS-SCLC  | 284 | Nivolumab + Ipiplumumab After Chemo-radiotherapy | Active          |
| NCT0418094   | First line | II | RCT | LS-SCLC | 140 | Sintilimab + EC/EP + RT vs EC/EP + RT | Not yet recruiting |
| NCT04925982  | Second line | II/III | Single arm | Relapsed | 40 | Sintilimab + Antiinib after Chemo-radiotherapy | Not yet recruiting |
| NCT0405792   | Beyond     | II | RCT | ES-SCLC | 52 | Sintilimab + Antiinib vs Antiinib | Recruiting |
| NCT03983759  | Maintenance | II | Single arm | ES-SCLC  | 40 | Sintilimab After Chemotheraphy + R-CIK | Recruiting |
| NCT04449861  | ORIENTAL  | First line | III | Single arm | ES-SCLC  | 300 | Durvalumab + EP/EP | Not yet recruiting |
| NCT0350912   | OLOVER    | First line | I | Multicohort | SCLC  | 380 | Durvalumab + Tremelmiumumab + EP/EP + Radiotherapy | Active          |
| NCT04361825  | Second line | II | Single arm | Relapsed | 45 | Durvalumab + AZD6738 | Recruiting |
| NCT02701400  | Second line | I | Parallel | Relapsed | 18 | Durvalumab + Tremelmiumumab + RT | Active          |
| NCT02937818  | Second line | II | Parallel | Refractory* | 72 | Durvalumab + Tremelmiumumab vs AZD1775 + carboplatin vs AZD6738 + Olaparib | Active          |
| NCT04314297  | Maintenance | II | Single arm | ES-SCLC  | 33 | Durvalumab + Antiinib after Chemo-radiotherapy | Not yet recruiting |
| NCT04478469  | Maintenance | II | Single arm | ES-SCLC  | 46 | RT + Durvalumab after Durvalumab + EC | Not yet recruiting |
| NCT0358998   | Maintenance | II | Single arm | LS-SCLC | 51 | Durvalumab after Chemo-radiotherapy + Durvalumab | Active          |
| NCT03703297  | ADRIATIC  | Maintenance | III | RCT | LS-SCLC | 600 | 4Durvalumab + 4Placebo;Durvalumab | Recruiting |
| NCT03923270  | SKYSCRAPER-02 | Maintenance | I | Parallel | ES-SCLC  | 54 | RT followed by Durvalumab or Durvalumab + Tremelmiumumab or Olaparib | Recruiting |
| NCT04258421  | First line | III | RCT | ES-SCLC | 400 | Atezolizumab + EC + Tiragolumab vs Atezolizumab + EC | Recruiting |
| NCT03313111  | First line | II | RCT | ES-SCLC | 105 | Atezolizumab + EC + Trilaciolbx(31T28) vs Atzeolizumab + EC | Active          |
| NCT03540420  | First line | II | RCT | LS-SCLC | 212 | Atezolizumab vs standard care after Chemo-radiotherapy | Recruiting |
| NCT04028050  | MAURIS    | First line | I/Ib | RCT | ES-SCLC | 150 | Atezolizumab + EC | Recruiting |
| NCT04422210  | Second line | I/Ib | Single arm | Relapsed | 62 | Venetoclax + Atezolizumab + EC | Recruiting |
| NCT03262454  | Second line | II | Single arm | Relapsed | 35 | Radiotherapy Followed by Atezolizumab | Recruiting |
| NCT03059967  | Second line | II | RCT | SCLC  | 70 | Atezolizumab + Topotecan/Toposide/Carboplatin | Active          |
| NCT04420788  | RAPTOR    | Second line | II/III | RCT | ES-SCLC | 324 | Atezolizumab + RT vs Atezolizumab | Not yet recruiting |
| NCT04308785  | Maintenance | II | RCT | LS-SCLC | 242 | Atezolizumab + EP/EP + radiotherapy vs EC/EP + radiotherapy | Not yet recruiting |
| NCT04148276  | TREASURE  | Maintenance | II | RCT | ES-SCLC | 104 | Atezolizumab + RT vs Atezolizumab after Atezolizumab + EC | Not yet recruiting |
| NCT03437309  | Maintenance | II | Single arm | ES-SCLC | 33 | Atezolizumab + Vornadil | Not yet recruiting |
| NCT03811002  | First line | II/III | RCT | LS-SCLC | 506 | Atezolizumab + EC/EP + RT vs EC/EP + RT | Recruiting |
| NCT04418648  | consolidation | II | RCT | LS-SCLC | 170 | Toripalimab vs Observation | Not yet recruiting |
| NCT04362355  | Maintenance | II | Single arm | ES-SCLC | 20 | EC/EP followed by Toripalimab + Antiinib | Recruiting |
| NCT04012606  | First line | III | RCT | ES-SCLC | 420 | Toripalimab(+S001) + EC/EP vs EP/EP | Recruiting |

*Platinum Refractory ES-SCLC.
FIGURE 2 | List of common irAEs for different ICIs (A: PD-1/PD-L1 inhibitors vs CTLA-4 inhibitors; B: PD-1 inhibitors vs PD-L1 inhibitors). Colored and black bar indicated the occurrence of irAEs of any grade and ≥ grade 3.

FIGURE 3 | Pooled analysis of neuromuscular toxicity in SCLC (A) and NSCLC (B).

FIGURE 4 | Summary of death events in SCLC trials. Each square represented one event, and different color stood for the causes of death. I, ICIs group; C, chemo/placebo group.
disease (n = 2), cardiotoxicity (n = 3), hepatitis (n = 3), and other unspecified cause (n = 2).

CONCLUSION

This paper reviewed the current status of immunotherapy in SCLC. Immunotherapy brings new hope to this formidable disease, and also unprecedented toxicity profile. Immunotherapy combined with either chemotherapy or other immunotherapies, led to higher occurrence of AE than immunotherapy alone. The toxicity of immunotherapy in SCLC seemed to be different with those in NSCLC, esp. for neuromuscular toxicity. This review may be helpful for the appropriate clinical use of immunotherapy for SCLC.

AUTHOR CONTRIBUTIONS

Z-YD and YZ contributed conception. YF drafted the manuscript, Z-YD reviewed the manuscript, and P-PW edited the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Byers LA, Rudin CM. Small Cell Lung Cancer: Where Do We Go From Here? Cancer (2015) 121(5):664–72. doi: 10.1002/cncr.29098
2. Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, et al. Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years. Clin Lung Cancer (2012) 13(2):115–22. doi: 10.1016/j.clc.2011.05.008
3. Socsinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy- Naive Patients With Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol (2009) 27(28):4787–92. doi: 10.1200/JCO.2009.23.1548
4. Fruh M, De Ruyscher D, Popat S, Crinò L, Peters S, Felip E, Esmo Guidelines Working Group. Small-Cell Lung Cancer (SCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2013) 24 Suppl 6:v99–105. doi: 10.1093/annonc/mdt178
5. Farago Anna F, Keane Florence K. Current Standards for Clinical Management of Small Cell Lung Cancer. Trans Lung Cancer Res (2018) 7:69–79. doi: 10.21037/tlcr.2018.01.16
6. Jones GS, Elinian K, Baldwin DR, Hubbard RB, McKeever TM. A Systematic Review of Survival Following Anti-Cancer Treatment for Small Cell Lung Cancer. Lung Cancer (2020) 141:44–55. doi: 10.1016/j.lungcan.2019.12.015
7. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of Extensive-Stage Small Cell Lung Carcinoma: Current Status and Future Prospects. Eur Respir J (2010) 35:202–15. doi: 10.1183/09031936.00105009
8. Mok TS, Wu Y-L, Ichinose Y, Herbst R, Kim S-W, Akerley W, et al. Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol (2019) 37:2180–8. doi: 10.1200/JCO.2018.83.1051
9. Huf Y-B, Zhang Q, Li H-J, Michot JM, Liu H-B, Zhan P, et al. Evaluation of Rare But Severe Immune Related Adverse Effects in PD-1 and PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Meta-Analysis. Transl Lung Cancer Res (2017) 6:58–20. doi: 10.21037/tlcr.2017.12.10
10. Johnson DB, Baldi JM, Compton ML, Chabot JA, Goheen J, Xu Y, et al. Pulmonary Myocarditis With Combination Immune Checkpoint Blockade. N Engl J Med (2016) 375:1749–55. doi: 10.1056/NEJMoa1609214
11. Gazdar AF, Bunn PA, Minna JD. Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward. Nat Rev Cancer (2017) 17 (12):725–37. doi: 10.1038/nrcl.2017.87
12. George J, Lim JS, Jang CJ, Sun Y, Oztetik L, Kong G, et al. Comprehensive Genomic Profiles of Small Cell Lung Cancer. Nature (2015) 524:47–53. doi: 10.1038/nature16646
13. Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux V, Vaquez C, et al. Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have Sclc With Neurologic Paraneoplastic Syndromes. J Thorac Oncol (2019) 14:1970–81. doi: 10.1016/j.jtho.2019.05.042
14. Yu H, Batenehuk C, Badzio A, Boyle TA, Czapiwetz P, Chan DC, et al. PD-L1 Expression by Two Complementary Diagnostic Assays and Mna In Situ Hybridization in Small Cell Lung Cancer. J Thorac Oncol (2017) 12:1120–20. doi: 10.1016/j.jtho.2016.09.002
15. Zhao X, Kallakury B, Chahine JJ, Hartmann D, Zhang Y, Chen Y, et al. Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. J Thorac Oncol (2019) 14:914–23. doi: 10.1016/j.jtho.2019.01.019
16. Turrisi AT, Kim K, Blum R, Sauve WT, Livingston RB, Komaki R, et al. Twice-Daily Compared With Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide. N Engl J Med (1999) 340:265–71. doi: 10.1056/NEJM199901283400403
17. Ardizzoni A, Hansen D, Dobrnosowsky P, Gammuci T, Kaplan S, Postmus P, et al. Topotecan, a New Active Drug in the Second-Line Treatment of Small-Cell Lung Cancer: A Phase II Study in Patients With Refractory and Sensitive Disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol (1997) 15:2090–6. doi: 10.1200/JCO.1997.15.5.2090
18. Sabri Joshua K, Hok Beniamin H, Laird James H, Poirier John T, Rudin Charles M. Unravelling the Biology of SCLC: Implications for Therapy. Nat Rev Clin Oncol (2017) 14:549–61. doi: 10.1038/nrclinonc.2017.71
19. Reck M, Bondarenoi I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Iplimumab in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Extensive-Disease-Small-Cell Lung Cancer: Results From A Randomized, Double-Blind, Multicenter Phase 2 Trial. Ann Oncol (2013) 24:75–83. doi: 10.1093/annonc/mds213
20. Reck M, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Iplimumab in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Extensive-Disease-Small-Cell Lung Cancer: Results From A Randomized, Double-Blind, Multicenter Phase 2 Trial. Ann Oncol (2013) 24:75–83. doi: 10.1093/annonc/mds213
21. Rudin CM, Awd MM, Navarro A, Gottfried M, Peters S, Calzati T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer, J Clin Oncol (2016) 34:3740–8. doi: 10.1200/JCO.2016.67.6601
22. Rudin CM, Awd MM, Navarro A, Gottfried M, Peters S, Calzati T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol (2020) 38:2369–79. doi: 10.1200/JCO.20.00793
